Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Bictegravir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    $ API Ref.Price (USD/KG) : 11,742Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 7Biktarvy

    02 5Descovy

    03 5Genvoya

    04 5Odefsey

    05 2Revenue share - Symtuza

    06 2Symtuza

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Symtuza

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    FNCE
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 488

    2019 Revenue in Millions : 379

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Descovy

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    FNCE
    Not Confirmed

    Brand Name : Descovy

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 1,861

    2019 Revenue in Millions : 1,500

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Odefsey

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    FNCE
    Not Confirmed

    Brand Name : Odefsey

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 1,672

    2019 Revenue in Millions : 1,655

    Growth (%) : 1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Biktarvy

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    FNCE
    Not Confirmed

    Brand Name : Biktarvy

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 7,259

    2019 Revenue in Millions : 4,738

    Growth (%) : 53

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Genvoya

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    FNCE
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 3,338

    2019 Revenue in Millions : 3,931

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Odefsey

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    FNCE
    Not Confirmed

    Brand Name : Odefsey

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 1,568

    2020 Revenue in Millions : 1,672

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Biktarvy

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    FNCE
    Not Confirmed

    Brand Name : Biktarvy

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 8,624

    2020 Revenue in Millions : 7,259

    Growth (%) : 19

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Genvoya

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    FNCE
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 2,879

    2020 Revenue in Millions : 3,338

    Growth (%) : -14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Symtuza

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    FNCE
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 531

    2020 Revenue in Millions : 488

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Descovy

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    FNCE
    Not Confirmed

    Brand Name : Descovy

    U.S.A
    arrow
    FNCE
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 1,700

    2020 Revenue in Millions : 1,861

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF